Observe Medical ASA: First half year 2026 interim report

Oslo, August 25, 2026 - Observe Medical ASA ("the Company" or "Observe
Medical") today publishes its financial report for the first half of 2026.

Operating revenues grew 27.4% year-over-year to NOK 14.4 million, driven by
increased sales volumes across the UnoMeterT portfolio, while the gross margin
improved to 29.5%. The balance sheet was materially strengthened following the
2025 debt restructuring and the wind-down of Biim Ultrasound, lifting the equity
ratio from 2.8% to 31.7%.

Highlights - first half 2026 (unaudited, H1 2025 in brackets)

  · Operating revenues of NOK 14.4 million (NOK 11.3 million), up 27.4% year
-over-year and 92% compared to the second half of 2025
  · Adjusted gross result of NOK 4.3 million (NOK 3.0 million), gross margin of
29.5% (+3.3pp)
  · Reported EBITDA of NOK 7.9 million (NOK -8.7 million), including a non-cash
gain of NOK 18.0 million from the Biim Ultrasound deconsolidation.
  · Adjusted EBITDA of NOK -8.3 million, excluding this gain and non-recurring
restructuring costs of NOK 2.0 million
  · Result for the period of NOK 5.6 million (NOK -19.0 million).

"Our global distribution platform is expanding and gaining traction, with an
expanding portfolio within the UnoMeterT family, our main priority for the
second half is to turn that momentum into sustainable revenue growth.

UnoMeterT SafetiT Max with UnoSafeCoatT technology combines infection
prevention, workflow efficiency and sustainability, and is designed to support
improved patient outcomes with more efficient use of healthcare resources. These
elements are building our position as we aim for commercial and clinical
leadership within our category.

Clinically relevant data on our patented UnoSafeCoatT technology has been
accepted for publication, solidifying the scientific foundation and commercial
credibility for both UnoMeterT SafetiT Max and UnoMeterT Sippi®, our next
-generation digital urimeter," says Jørgen Mann, CEO of Observe Medical.

The complete half-year report for 2026 is attached to this announcement and is
available at www.observemedical.com.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available
at www.observemedical.com and www.linkedin.com/company/Observe-Medical
rmation is available\
at www.observemedical.com and www.linkedin.com/company/Observe-Medical\